Two pharma companies developing lipid-lowering drugs, MSD and Ionis, have reported positive phase 3 data that open the way for regulatory filings in the coming months. First up, MSD, which chalked up ...
MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection for blockbuster cancer drug Keytruda the following year. The plan was ...
After 10 weeks of training at IMG Academy in Florida, 13 athletes from the International Player Pathway program will take the field for a workout in front of NFL scouts. IPP consultant Scott Pioli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback